Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: Experience of a tertiary cancer referral centre in India.
Loading...
Date
2010-09
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background & objective: Determination of HER2 status in breast cancer has become important to identify potential candidates for anti-HER2 therapy. In this study we compared fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) for the determination of HER2 status in breast cancer patients referred to a tertiary care referral centre.
Methods: A total of 200 cases of invasive breast cancer were evaluated for HER2 status using IHC and FISH and results were compared.
Results: The IHC 3+ (93.9%) and IHC negative (85.9%) cases showed good concordance with the corresponding FISH results; while 66.6 per cent of IHC 2+ cases showed gene amplification by FISH. In addition, hormone receptor expression and HER2 gene status showed a statistically significant inverse association (P<0.05).
Interpretation & conclusion: These findings reaffirm IHC as a prudent first-step to screen tissue samples for HER2 status and to determine suitability for technically demanding FISH test and the dual coloured FISH as a gold standard for determination of HER2/neu status in IHC equivocal cases of breast carcinoma.
Description
Keywords
Breast cancer, fluorescent in situ hybridization (FISH), HER2/neu, immunohistochemistry (IHC), trastuzumab
Citation
Panjwani Poonam, Epari Sridhar, Karpate Arti, Shirsat Hemlata, Rajsekharan Preetha, Basak Ranjan, Shet Tanuja, Chinoy Roshni, Chacko Roy, Gursale Sampada, Baraskar Nayana, Gupta Sudeep, Hawaldar Rohini, Desai Sangeeta. Assessment of HER-2/neu status in breast cancer using fluorescence in situ hybridization & immunohistochemistry: Experience of a tertiary cancer referral centre in India. Indian Journal of Medical Research. 2010 Sept; 132(3): 287-294.